| [1] |
CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南[M].2013版.北京：人民卫生出版社，2013：17-18.
|
| [2] |
Ferlay J，Steliarova-Foucher E，Lortet-Tieulent J，et al.Cancer incidence andmortality patterns in Europe：estimates for 40 countries in 2012[J].Eur JCancer，2013，49（6）：1374-1403.
|
| [3] |
Zuidervaart W，Van Nieuwpoort F，Stark M，et al.Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS[J].Br JCancer，2005，92（11）：2032-2038.
|
| [4] |
Bollag G，Hirth P，Tsai J，et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma[J].Nature，2010，467（7315）：596-599.
|
| [5] |
Chapman PB，Hauschild A，Robert C，et al.Improved survivalwith vemurafenib inmelanomawith BRAF V600Emutation[J].N Engl JMed，2011，364（26）：2507-2516.
|
| [6] |
Hauschild A，Grob JJ，Demidov LV，et al.Dabrafenib in BRAF-mutated metastatic melanoma：a multicentre，openlabel，phase 3 randomised controlled trial[J].Lancet，2012，380（9839）：358-365.
|
| [7] |
Dummer R，Robert C，Gutzmer R，et al.Selumetinib plus dacarbazine versus placebo plus dacarbizine as first-line treatment for BRAF-mutantmetastaticmelanoma：a phase 2 doubleblind randomized study[J].Lancet Oncol，2013，14（8）：733-740.
|
| [8] |
Flaherty KT，Robert C，Hersey P，et al.Improved survival with MEK inhibition in BRAF-mutated melanoma[J].N Engl JMed，2012，367（2）：107-114.
|
| [9] |
Sosman JA，Kim KB，Schuchter L，et al.Survival in BRAF V600-mutantadvancedmelanoma treatedwith vemurafenib[J]. N Engl JMed，2012，366（8）：707-714.
|
| [10] |
Falchook GS，Long GV，Kurzrock R，et al.Dabrafenib in patients with melanoma，untreated brain metastases，and other solid tumours：a phase 1 dose-escalation trial[J]. Lancet，2012，379（9829）：1893-1901.
|
| [11] |
Porcelli L，Guida G，Tommasi S，et al.Metastatic melanoma cells with BRAF G469A mutation：nab-paclitaxel better than vemurafenib[J].Cancer Chemother Pharmacol，2015，76（2）：433-438.
|
| [12] |
Anforth R，Fernandez-Penas P，Long GV.Cutaneous toxicities of RAF inhibitors[J].Lancet Oncol，2013，14（1）：11-18.
|
| [13] |
Menzies AM，Yeh I，Botton T，et al.Clinical activity of the MEK inhibitor trametinib in metastatic melanomacontaining BRAF kinase fusion[J].Pigment Cell Melanoma Res，2015，28（5）：607-610.
|
| [23] |
Settleman J.A therapeutic opportunity in melanoma：ErbB4 makes a mark on skin[J].Cancer Cell，2009，16（4）：278-279.
|
| [14] |
Ascierto PA，Schadendorf D，Berking C，et al.MEK162 for patients with advanced melanomaharbouring NRAS or Val600 BRAF mutations：a non-randomised，open-labelphase 2 study[J].Lancet Oncol，2013，14（3）：249-256.
|
| [15] |
Ascierto PA，Minor D，Ribas A，etal.PhaseⅡtrial（BREAK-2）of the BRAF inhibitor dabrafenib（GSK2118436）in patientswith metastatic melanoma[J].JClin Oncol，2013，31（26）：3205-3211.[16]Larkin J，Ascierto PA，Dréno B，et al.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma[J].N Engl JMed，2014，371（20）：1867-1876.
|
| [17] |
Robert C，Karaszewska B，Schachter J，et al.Improved overall survival in melanoma with combined dabrafenib and trametinib[J].N Engl JMed，2015，372（1）：30-39.
|
| [18] |
Ribas A，Gonzalez R，Pavlick A，et al.Combination of vemurafenib and cobimetinib in patients with advanced BRAF（V600）-mutated melanoma：a phase 1b study[J]. Lancet Oncol，2014，15（9）：954-965.
|
| [19] |
Sullivan RJ，Weber JS，Patel SP，et al.A phaseⅠb/Ⅱstudy of BRAF inhibitor（BRAFi）encorafenib（ENCO）plus MEK inhibitor（MEKi）binimetinib（BINI）in cutaneous melanoma patients naive to BRAFi treatment[J].ASCO Meet Abstr，2015，33（15）：9007.
|
| [20] |
Woodman SE，Trent JC，Stemke-Hale K，et al.Activity of dasatinib against L576PKITmutantmelanoma：molecular，cellular，and clinical correlates[J].Mol Cancer Ther，2009，8（8）：2079-2085.
|
| [21] |
Patel SP，Kim KB，Papadopoulos NE.A phaseⅡstudy of gefitinib in patientswithmetastaticmelanoma[J].Melanoma Res，2011，21（4）：357-363.
|
| [22] |
Schicher N，Paulitschke V，Swoboda A，et al.Erlotinib and bevacizumab have synergistic activity againstmelanoma[J]. Clin Cancer Res，2009，15（10）：3495-3502.
|
| [24] |
Djerf Severinsson EA，Trinks C，Grren H.The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis ofmalignantmelanoma in vitro and displays anti-tumor activity in vivo[J].Biochem Biophys Res Commun，2011，414（3）：563-568.
|
| [25] |
Soni S，Lee DS，DiVito J Jr，et al.Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide[J].JPediatr Hematol Oncol，2002，24（6）：488-491.
|
京公网安备 11010502046607号